CAJ | 학술논문

目的观察丹红注射液联合辛伐他汀对急性冠状动脉综合征(ACS)患者血脂水平和超敏C反应蛋白(hs-CRP)的影响.方法随机将246例ACS患者分为对照组和实验组,治疗8周,比较治疗前后血脂水平和hs-CRP变化.结果两组中血脂水平和hs-CRP均有不同程度的改变,实验组下降更明显,与对照组相比,差异有统计学意义(P<0.05).结论丹红注射液联合辛伐他汀治疗ACS患者能够显著降低其血脂水平和血浆hs-CRP,对ACS的诊治、判定预后及稳定粥样斑块等有积极意义.
목적관찰단홍주사액연합신벌타정대급성관상동맥종합정(ACS)환자혈지수평화초민C반응단백(hs-CRP)적영향.방법수궤장246례ACS환자분위대조조화실험조,치료8주,비교치료전후혈지수평화hs-CRP변화.결과량조중혈지수평화hs-CRP균유불동정도적개변,실험조하강경명현,여대조조상비,차이유통계학의의(P<0.05).결론단홍주사액연합신벌타정치료ACS환자능구현저강저기혈지수평화혈장hs-CRP,대ACS적진치、판정예후급은정죽양반괴등유적겁의의.
Objective To observe Danhong injection combined with simvastatin lipid levels and high-sensitivity C-reactive protein (hs-CRP) in patients with acute coronary syndrome (ACS). Method 246 patients with ACS randomly divided into a control group and an experimental group, eight weeks of treatment, comparing the treatment of blood lipid levels and hs-CRP changes. Results The two groups in blood lipid levels and hs-CRP in varying degrees of change, the experimental group decreased significantly, compared with the control group, the difference was statistically significant (P<0.05). Conclusion Danhong injection combined with simvastatin treatment of ACS patients can significantly reduce blood lipid levels and plasma hs-CRP, the diagnosis and treatment of ACS, determine prognosis and stable atherosclerotic plaques positive significance.